MBX Biosciences, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MBX research report →
Range $84 – $150
Price Chart
About the company
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials.
- CEO
- Steve Hoerter
- IPO
- 2024
- Employees
- 63
- HQ
- Carmel, IN, US
Get TickerSpark's AI analysis on MBX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.46B
- P/E
- -16.55
- PEG
- 0.57
- P/S
- 0.00
- P/B
- 5.20
- EV/EBITDA
- -15.86
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -34.35%
- ROIC
- -33.67%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-248,000+0.0%
- Op Income
- $-98,055,000
- Net Income
- $-86,971,000-40.5%
- EPS
- $-2.38-28.6%
- OCF Growth
- -46.2%
- FCF Growth
- -47.4%
- 52W High
- $72.64
- 52W Low
- $26.00
- 50D MA
- $55.07
- 200D MA
- $46.62
- Beta
- 0.10
- RSI (14)
- 43
- Avg Volume
- 531.00K
No earnings-call transcripts are available for MBX yet.
- Free Float
- 43.5%
- Shares Outstanding
- 49.66M
- Float Shares
- 21.60M
of shares held by institutions
182 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 7.37M | ▲ 2.05M |
| Frazier Life Sciences Management, L.P. | 6.65M | 0 |
| Wellington Management Group Llp | 5.16M | ▲ 187.01K |
| Paradigm Biocapital Advisors LP | 3.77M | ▲ 1.26M |
| Nea Management Company, LLC | 3.61M | 0 |
| Blackrock, Inc. | 3.47M | ▲ 149.78K |
| Orbimed Advisors LLC | 3.07M | ▼ 353.88K |
| Nvp Associates, LLC | 2.14M | 0 |
| Vanguard Group Inc | 1.82M | ▲ 140.45K |
| Polar Capital Holdings PLC | 1.60M | ▼ 4.93K |
| Vanguard Capital Management LLC | 1.43M | ▼ 46.49K |
| Aaron Wealth Advisors LLC | 1.18M | ▲ 7.97K |
Held by 253 ETFs
Biggest fund positions in MBX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Hoerter Steven L. | sell | 4,893 |
| Nov 4, 26 | Azoulay Salomon | sell | 373 |
| Oct 20, 26 | Radovich Peter | other | 18,200 |
| Oct 20, 26 | Radovich Peter | other | 0 |
| Aug 4, 26 | Azoulay Salomon | sell | 370 |
| Aug 3, 26 | Smither John W | other | 130,000 |
| Aug 3, 26 | Smither John W | other | 28,000 |
| Aug 3, 26 | Hoerter Steven L. | other | 331,000 |
| Aug 3, 26 | Hoerter Steven L. | other | 71,000 |
| Jun 4, 26 | Mathers Edward T | other | 12,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MBX coverage
Recent articles, reports, and earnings notes.
No research on MBX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MBX report →MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com · Nov 9
Microbix Attending & Presenting at IPVS 2026
accessnewswire.com · Oct 19
MBX Biosciences to Participate in Upcoming November Investor Conferences
globenewswire.com · Oct 13
MBX Biosciences (NASDAQ:MBX) Shares Climb 4.1% – Time to Buy?
defenseworld.net · Sep 30
MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DE
defenseworld.net · Sep 25
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)
seekingalpha.com · Sep 23
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
fool.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.